Active Low-Carber Forums
Atkins diet and low carb discussion provided free for information only, not as medical advice.
Home Plans Tips Recipes Tools Stories Studies Products
Active Low-Carber Forums
A sugar-free zone


Welcome to the Active Low-Carber Forums.
Support for Atkins diet, Protein Power, Neanderthin (Paleo Diet), CAD/CALP, Dr. Bernstein Diabetes Solution and any other healthy low-carb diet or plan, all are welcome in our lowcarb community. Forget starvation and fad diets -- join the healthy eating crowd! You may register by clicking here, it's free!

Go Back   Active Low-Carber Forums > Main Low-Carb Diets Forums & Support > Low-Carb Studies & Research / Media Watch > LC Research/Media
User Name
Password
Register FAQ Members Calendar Mark Forums Read Search Gallery My P.L.A.N. Survey


Reply
 
Thread Tools Display Modes
  #1   ^
Old Sat, Dec-02-06, 23:05
2bthinner!'s Avatar
2bthinner! 2bthinner! is offline
Senior Member
Posts: 3,345
 
Plan: Paleo Gluten free
Stats: 242/216/130 Female 5'7.5"
BF:too/dang/much
Progress: 23%
Location: Florida
Default Pfizer ends cholesterol drug development

http://news.yahoo.com/s/ap/20061203...holesterol_drug

Pfizer ends cholesterol drug development 2 hours, 24 minutes ago



Pfizer Inc. said Saturday it has cut off all clinical trials and development for a cholesterol drug that was supposed to be the star of its pipeline because of an unexpected number of deaths and cardiovascular problems in patients who used it.

The world's largest drugmaker said it was told Saturday that an independent board monitoring a study for torcetrapib, a drug that raises levels of HDL, or what's commonly known as good cholesterol, recommended that the work end because of "an imbalance of mortality and cardiovascular events."

Pfizer said it is asking all clinical investigators conducting trials to warn patients to stop taking the drug immediately.

The news is devastating to Pfizer, which had been counting on the drug to revitalize stagnant sales that have been hurt by numerous patent expirations on key products.

Just two days ago, Pfizer had said it hoped to file an application with the Food and Drug Administration for approval of torcetrapib by the second half of next year. But on Saturday, the company said the loss of the drug will not affect its financial guidance for 2006.

New York-based Pfizer had expected to sell Torcetrapib in combination with Lipitor, which lowers bad cholesterol and is the company's and the world's best-selling drug.

According to Pfizer spokesman Paul Fitzhenry, 82 patients taking the combination of torcetrapib died, compared to 51 deaths in the arm of the study where patients were taking Lipitor alone. Each arm of the study had 7,500 patients. Pfizer said that the study didn't raise any questions about Lipitor's safety.

There already had been concerns about Torcetrapib because a study showed it caused an increase in blood pressure. In raising its earnings guidance for the year Thursday the company emphasized that it has 242 research programs and other promising drugs in the pipeline, but analysts remained focused on Torcetrapib and said Pfizer would struggle without it.

Patent expirations will cost the company $14 billion in annual sales between 2005 and 2007, the company said. Lipitor, which had $12.2 billion in sales last year, may lose patent protection by 2010.

Dr. Philip Barter, chairman of the steering committee overseeing the study, said in Pfizer's release that the findings of the data safety monitoring board Torcetrapib were a surprise "in light of prior study results."

"We believed that the study was coming along as expected, and this new information was totally unexpected and disappointing, given the potential benefits of this drug," said Barter, Director of the Heart Research Institute in Australia.


~~~~~~~~~~~~~
I should print this out and take it to my doctor. (I refused to take any medication for my cholesterol.) My mom, lets him write her a prescription, but never fills it...
Reply With Quote
Sponsored Links
  #2   ^
Old Sun, Dec-03-06, 06:18
Absinthe62's Avatar
Absinthe62 Absinthe62 is offline
Senior Member
Posts: 243
 
Plan: Protein Power
Stats: 195/185/140 Female 5'3"
BF:Well-marbled
Progress: 18%
Location: Fort Collins, CO
Default

Quote:
Patent expirations will cost the company $14 billion in annual sales


OMG, the first time I read that I thought it said "patient expirations" and was ready to blow a gasket at the terminology.

Interesting that the 51 Lipitor-related deaths during the study aren't a concern to them.
Reply With Quote
  #3   ^
Old Sun, Dec-03-06, 08:42
seyont seyont is offline
Senior Member
Posts: 243
 
Plan: parts of them all
Stats: 181/166/165 Male 5' 8"
BF:25%/9%/12%
Progress: 94%
Default

I realize that the 51 deaths in the Lipitor group is probably less than a control group would be and 82 deaths is more, but still, with 242 research projects going on, that's a lot of death to oversee.
Reply With Quote
  #4   ^
Old Sun, Dec-03-06, 10:39
CindySue48's Avatar
CindySue48 CindySue48 is offline
Senior Member
Posts: 2,816
 
Plan: Atkins/Protein Power
Stats: 256/179/160 Female 68 inches
BF:38.9/27.2/24.3
Progress: 80%
Location: Triangle NC
Default

Quote:
Originally Posted by seyont
I realize that the 51 deaths in the Lipitor group is probably less than a control group would be and 82 deaths is more, but still, with 242 research projects going on, that's a lot of death to oversee.
That's a lot of people that died after trusting their docs and the drug companies, and "the system" to put their best interests at heart.

Sad that people are just brushed aside like this. The numbers aren't important....unless you're talking dollars and cents.
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off



All times are GMT -6. The time now is 21:55.


Copyright © 2000-2018 Active Low-Carber Forums @ forum.lowcarber.org
Powered by: vBulletin, Copyright ©2000 - 2018, Jelsoft Enterprises Ltd.